News
Try it free for 7 days Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback